Viatris has agreed to acquire Pacira BioSciences in an all-cash transaction valued at $1.65 billion, paying $36.50 per share for the maker of non-opioid pain therapies. The companies announced the definitive agreement on Thursday.
Under the terms, Viatris will commence a tender offer for all outstanding shares of Pacira common stock. The offer is subject to customary conditions, including a minimum condition that the shares tendered, together with any already owned by Viatris and its affiliates, represent at least one share more than 50% of the total outstanding. The deal is anticipated to close by the end of 2026.
Strategically, the acquisition adds two marketed, patent-protected, high-margin medicines in the United States, EXPAREL and ZILRETTA. EXPAREL is a long-acting local anesthetic used to manage pain after surgery, while ZILRETTA is an extended-release injection for osteoarthritis pain of the knee. Viatris said it expects to expand the reach of both products across selected markets by using its international commercial infrastructure.
Viatris CEO Scott Smith called the pending acquisition an important step in building the company's innovative medicines business. The company also said the deal expands its U.S. commercial, market access, medical affairs and global research and development capabilities, and is expected to be synergistic with its fast-acting meloxicam opportunity. Management expects the transaction to be immediately accretive to its financial guidance metrics and to preserve financial flexibility.
The transaction fits a broader pattern in which established pharmaceutical companies pivot from mature, price-pressured generics toward differentiated branded assets with longer patent runways. Non-opioid pain therapies have drawn strategic interest because clinicians and health systems have been working to reduce reliance on opioids after surgery and in chronic pain management. Owning two commercial-stage products in that category gives Viatris a larger direct presence with surgeons, anesthesiologists and orthopedic specialists.
For Pacira holders, the all-cash price sets a clear reference point. In merger arbitrage situations, a target's shares typically trade modestly below the offer price until closing, reflecting the time value of money and the risk of regulatory or tender-offer delays. Investors should watch for antitrust review, the tender-offer expiration date and any sign of a competing bid, although none was reported in the announcement.
For Viatris shareholders, the key questions are integration and balance-sheet impact. Management says the deal preserves financial flexibility, but the market will want to see how quickly the two products can grow under Viatris' commercial platform and how the use of cash or debt affects capital allocation. With the 10-year Treasury yield near 5.3%, financing costs are a live consideration for any acquirer this year. The deal arrives on a day when broader equities are under pressure from oil prices and rates, which makes a defined cash price in healthcare a relatively insulated corner of the market. This is analysis, not investment advice.